- AstraZeneca will terminate ADS trading on Nasdaq on January 30, 2026 and start trading in ordinary shares at the NYSE from February 2,2026
- The United States is AstraZeneca's single-largest market, accounting for over 40% of its earnings
- Delisting from Nasdaq and listing on NYSE will give the company's access to a a wider capital pool
AstraZeneca has reitereted that it will delist from Nasdaq after market close on January 30 and start trading on the New York Stock Exchange (NYSE) from February 2. This shift is a strategic one, but why would a company worth over $200 billion make this move, and what does it mean for the company and its investors?
Why Is AstraZeneca Delisting from Nasdaq?
AstraZeneca wants to focus its global presence, and the U.S. is its biggest market. The main reason for the change is to sync the company’s stock listings. The board wants its shares to trade on the London Stock Exchange, Nasdaq Stockholm, and now the NYSE. This will replace the American Depositary Receipts on Nasdaq. Analysts say the shift enables AstraZeneca to take advantage of the strong U.S. stock market, where they get over 40% of their earnings
As outlined in the company’s September 2025 press release, this upgrade to a direct listing of ordinary shares on the NYSE simplifies the equity structure without altering its UK headquarters or tax residency. Reuters reports that this allows AstraZeneca to capitalize on the booming U.S. stock market, where over 40% of its revenues originate, while defusing earlier speculations about a full UK exit.
The company’s chairman, Michel Demaré, mentioned that this move enables the company get money from the largest pool possible. Given how important the American market is, the company wants to make it easy for American investors to own the same shares traded in London.
What Does This Mean for Investors?
If you own AstraZeneca ADRs on the Nasdaq, there is no need to stress. The company has made it clear that the switch should be smooth, even with the conversion from ADRs. The ADRs, which used to represent ordinary shares on a 2-for-1 basis, will become shares, making the transition simpler.
Also, the stock ticker will still be AZN and will trade on the NYSE. U.S. investors can buy shares directly without ADR fees, which makes things better. There might be some ups and downs during the changeover. but it could lead to value over time since it’s easier to get to the market.
Beyond the paperwork, this move is a massive vote of confidence in the U.S. market. It follows AstraZeneca’s massive commitment to invest $50 billion into U.S. manufacturing and R&D over the next five years. CNBC notes that CEO Pascal Soriot has emphasized the company’s “very American” orientation, amid frustrations with UK drug-pricing regimes that led to paused investments in Cambridge and Liverpool.
AZN Stock Price Prediction
AZN stock’s pivot point is at psychological $93.00 mark, with the RSI at 56.71, which favours the upside. The MACD is at 1.20, which affirms the likelihood of movement towards the upper direction. If the stock breaks above $95.35, it could target $96.50. Key support levels include $91.50 and $90.00.
AstraZeneca stock daily chart with key support and resistance levels on January 20,2026. Created on TradingView
The move helps to list ordinary shares directly on the NYSE instead of using ADRs. This makes the trading structure easier and helps the company access a bigger pool of global capital.
The outlook is generally positive. By making liquidity and visibility better in its largest market, the company wants to get more institutional investors, supported by its $50 billion investment in U.S. operations.
It makes trading easier by removing ADR fees and keeping the AZN ticker, which could make liquidity and access better.